Delivery Order SPE2DB20D9331-SPE2DB25FL0Q0

Award Date 1/24/25
Potential Completion Date 2/14/25
Potential Value $8.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,556.54, is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of December 15, 2023 and was awarded on November 24, 2023. DMS Pharmaceutical Group Inc. is the prime contractor for this award. The company specializes...
This firm-fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a specialized pharmaceutical product, with a ceiling value of $1,691.16. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB program. The $3,268.08 award is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML to fulfill the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,634.04, was awarded by the Defense Logistics Agency (DLA) and has an ultimate completion date of June 18, 2024. The contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, which is a pharmaceutical product. DMS Pharmaceutical Group Inc. has an Indefinite Delivery Contract (IDC) with...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,556.52, is for the delivery of a pharmaceutical product, specifically VisionBlue 0.06% Syringe 0.5ML. The contract has a completion date of September 8, 2023 and is a firm fixed-price delivery order. DMS Pharmaceutical Group Inc. holds a larger...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,634.04 contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a specialized pharmaceutical product. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which allows the DLA to...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is a firm fixed-price delivery order under the Defense Logistics Agency's (DLA) SPE2DB prime vendor program. The $1,556.52 contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML pharmaceutical products to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of...
This is a Firm Fixed Price Delivery Order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $6,536.16, is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a specialized pharmaceutical product, with a period of performance through December 6, 2024. This order is issued under a larger Indefinite Delivery Contract (IDC) with a ceiling value of...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB24 program. The $3,268.08 award is for the supply of a 0.5mL syringe containing 0.06% VisionBlue solution. The order does not have a set-aside designation. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,634.04 firm fixed-price delivery order is for the supply of the pharmaceutical product "VISIONBLUE 0.06% SYRINGE 0.5ML" to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC)...
  • SPE2DB20D9331
    Indefinite Delivery Contract
  • SPE2DB20D9331-SPE2DB25FL0Q0
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract has a ceiling value of $8,455.80 and an ultimate completion date of February 14, 2025. The contract provides for the delivery of a specialized pharmaceutical product, VISIONBLUE 0.06% SYRINGE 0.5ML, to support the medical supply needs of the Department of Defense (DoD) healthcare facilities. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items. This contract is not associated with any set-aside designation, allowing DMS Pharmaceutical Group Inc. to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains.

Generated 4/25/25, 10:05 AM